CO2023006811A2 - Mayor eficiencia del empaquetamiento de vectores para terapia génica cardíaca - Google Patents

Mayor eficiencia del empaquetamiento de vectores para terapia génica cardíaca

Info

Publication number
CO2023006811A2
CO2023006811A2 CONC2023/0006811A CO2023006811A CO2023006811A2 CO 2023006811 A2 CO2023006811 A2 CO 2023006811A2 CO 2023006811 A CO2023006811 A CO 2023006811A CO 2023006811 A2 CO2023006811 A2 CO 2023006811A2
Authority
CO
Colombia
Prior art keywords
compositions
methods
cardiac
gene therapy
carc
Prior art date
Application number
CONC2023/0006811A
Other languages
English (en)
Inventor
Hugh Lee Sweeney
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of CO2023006811A2 publication Critical patent/CO2023006811A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4728—Calcium binding proteins, e.g. calmodulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Electrotherapy Devices (AREA)

Abstract

La presente descripción se relaciona con composiciones y métodos útiles en el tratamiento de afecciones cardíacas. Las composiciones y los métodos descritos se basan en terapias génicas que comprenden un vector AAV recombinante para administrar dos o más transgenes en el corazón de un sujeto, donde los transgenes codifican una proteína S100A1 y un inhibidor del Represor de la Apoptosis Cardiaca con Dominio de Reclutamiento de Caspasa (cARC), respectivamente. En diversas realizaciones, las composiciones y los métodos descritos en este documento comprenden vectores que comprenden secuencias de ADNc de S100A1 y/o cARC que tienen codones optimizados para la expresión en seres humanos. En diversas realizaciones, las composiciones y los métodos descritos en este documento comprenden vectores con eficiencias de empaquetamiento mejoradas. En algunos aspectos, enfocarse en múltiples fuentes de una o más afecciones cardíacas puede brindar beneficios sinérgicos durante el tratamiento.
CONC2023/0006811A 2020-12-23 2023-05-25 Mayor eficiencia del empaquetamiento de vectores para terapia génica cardíaca CO2023006811A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063130109P 2020-12-23 2020-12-23
PCT/US2021/064637 WO2022140402A1 (en) 2020-12-23 2021-12-21 Increased packaging efficiency of vector for cardiac gene therapy

Publications (1)

Publication Number Publication Date
CO2023006811A2 true CO2023006811A2 (es) 2023-05-29

Family

ID=80445607

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0006811A CO2023006811A2 (es) 2020-12-23 2023-05-25 Mayor eficiencia del empaquetamiento de vectores para terapia génica cardíaca

Country Status (14)

Country Link
US (1) US20240139343A1 (es)
EP (1) EP4267749A1 (es)
JP (1) JP2024501957A (es)
KR (1) KR20230124979A (es)
CN (1) CN116867512A (es)
AR (1) AR124506A1 (es)
AU (1) AU2021409806A1 (es)
CA (1) CA3205116A1 (es)
CL (1) CL2023001731A1 (es)
CO (1) CO2023006811A2 (es)
IL (1) IL303860A (es)
MX (1) MX2023007602A (es)
TW (1) TW202242120A (es)
WO (1) WO2022140402A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5962313A (en) 1996-01-18 1999-10-05 Avigen, Inc. Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
US20070015238A1 (en) 2002-06-05 2007-01-18 Snyder Richard O Production of pseudotyped recombinant AAV virions
US20120322861A1 (en) 2007-02-23 2012-12-20 Barry John Byrne Compositions and Methods for Treating Diseases
US20200308582A1 (en) * 2017-10-12 2020-10-01 Universität Heidelberg Kcnk3-based gene therapy of cardiac arrhythmia
BR112020024935A2 (pt) 2018-06-08 2021-03-09 University Of Florida Research Foundation, Incorporated Terapia gênica cardíaca com aav para cardiomiopatia
AU2020229382A1 (en) * 2019-02-28 2021-09-16 Encoded Therapeutics, Inc. Compositions and methods for treating laminopathies
CN114206351A (zh) * 2019-07-19 2022-03-18 佛罗里达大学研究基金会有限公司 用于人中心肌病的aav心脏基因治疗

Also Published As

Publication number Publication date
EP4267749A1 (en) 2023-11-01
KR20230124979A (ko) 2023-08-28
CL2023001731A1 (es) 2023-12-15
JP2024501957A (ja) 2024-01-17
AU2021409806A9 (en) 2024-02-08
TW202242120A (zh) 2022-11-01
US20240139343A1 (en) 2024-05-02
CN116867512A (zh) 2023-10-10
CA3205116A1 (en) 2022-06-30
AU2021409806A1 (en) 2023-06-15
AR124506A1 (es) 2023-04-05
WO2022140402A1 (en) 2022-06-30
IL303860A (en) 2023-08-01
MX2023007602A (es) 2023-09-21

Similar Documents

Publication Publication Date Title
CL2022000115A1 (es) Terapia genética cardíaca con aav para la cardiomiopatía en humanos.
CO2020016718A2 (es) Terapia génica cardíaca con aav para cardiomiopatía
CO2021008120A2 (es) Vectores virales recombinantes y ácidos nucleicos para producirlos
CL2022000900A1 (es) Proteínas heterodiméricas fusionadas con fc. (divisional de solicitud 202101058)
BR112018002046A2 (pt) métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina
Grzech-Lesniak Making use of lasers in periodontal treatment: a new gold standard
PE20181922A1 (es) Terapia genica para tratar la hemofilia a
AR116700A1 (es) Generación de una mejor fenilalanina hidroxilasa hepática humana para el tratamiento de la fenilcetonuria severa por terapia génica de reemplazo directo en el hígado
ES2722623T3 (es) Conjuntos de adaptador para la interconexión de conjuntos de mango electromecánico y unidades de carga quirúrgica
CO2023006811A2 (es) Mayor eficiencia del empaquetamiento de vectores para terapia génica cardíaca
AR118997A1 (es) Partículas virales modificadas y usos de estas
NI201500057A (es) Métodos para reducir riesgos asociados con insuficiencia cardiaca y factores asociados
BR112022007324A2 (pt) Dispositivos ou métodos para modular atividade de sistema imunológico em um paciente com câncer ou tratar câncer
ECSP20055797A (es) Métodos y composiciones para tratar enfermedades pulmonares crónicas
CO2021016487A2 (es) Vectores aav con el promotor de la proteína cero de mielina y usos de los mismos para el tratamiento de enfermedades asociadas a las células de schwann como la enfermedad de charcot-marie-tooth
JP2021514725A5 (es)
CL2023001876A1 (es) Proteínas de la cápside viral con especificidad para las células del tejido cardiaco
AR117877A1 (es) Rhabdovirus recombinante que codifica ccl21
Kazemikhoo et al. Effects of photobiomodulation and split-thickness skin grafting in the prognosis of wound healing in children with deep burn ulcers
EP4171411A1 (en) Split biphasic waveform for embolic reduction
ES2654845A1 (es) Dispositivo que combina tecnología laser con ozono y su uso en un método de tratamiento de infecciones micóticas
Wang et al. Comparison of rectilinear biphasic waveform with biphasic truncated exponential waveform in a pediatric defibrillation model
Wollina et al. The use of biophysical technologies in chronic wound management
Na et al. Low-level green and red laser treatment of Shaochong (HT9)· Dadun (LR1) and Shaohai (HT3)· Yingu (KI10) acupoints in a rat model of focal cerebral ischemia
JP2022099207A (ja) 貧血治療薬